BACKGROUND: Concurrent platinum-based chemoradiation significantly improved survival of advanced stage cervical patients over radiotherapy alone. However, the 5-year overall survival is still only 66%. Presently, no biomarkers are available to select those cervical cancer patients that might benefit from concurrent platinum-based chemoradiation therapy. DNA methylation is a well-established contributor to the regulation of gene transcription, predominantly causing transcriptional silencing. Differences in promoter hypermethylation patterns and subsequent silencing, could contribute to the variety of responses observed in clinical practice. Several clinical trials on various malignancies reported a better response when Decitabine was administered prior to or in combination with standard therapy. This sensitization is thought to be due to re-expression of tumor suppressor genes. However, not all patients might benefit from demethylating agents, since re-expression of oncogenes could render patients more resistant. AIM: In this review, we summarized the present state of art regarding hypermethylated genes and their affected signaling pathways that are associated with outcome after cisplatin treatment, radiotherapy or chemoradiation. Since only few studies were reported in cervical cancer, other malignancies were reviewed as well. CONCLUSIONS: From the data presented in this review, we conclude that, in order to select patients that benefit most optimally from demethylating strategies, a comprehensive screening of a large panel of methylation markers, associated with both good as well as poor clinical outcome have to be investigated. Since such panels are not available at this moment, global methylation screening approaches are required to profile such methylated genes. Such methylated gene profiles might be very useful to optimize personalized treatment planning not only in cervical cancer but also in other malignancies.
BACKGROUND: Concurrent platinum-based chemoradiation significantly improved survival of advanced stage cervical patients over radiotherapy alone. However, the 5-year overall survival is still only 66%. Presently, no biomarkers are available to select those cervical cancerpatients that might benefit from concurrent platinum-based chemoradiation therapy. DNA methylation is a well-established contributor to the regulation of gene transcription, predominantly causing transcriptional silencing. Differences in promoter hypermethylation patterns and subsequent silencing, could contribute to the variety of responses observed in clinical practice. Several clinical trials on various malignancies reported a better response when Decitabine was administered prior to or in combination with standard therapy. This sensitization is thought to be due to re-expression of tumor suppressor genes. However, not all patients might benefit from demethylating agents, since re-expression of oncogenes could render patients more resistant. AIM: In this review, we summarized the present state of art regarding hypermethylated genes and their affected signaling pathways that are associated with outcome after cisplatin treatment, radiotherapy or chemoradiation. Since only few studies were reported in cervical cancer, other malignancies were reviewed as well. CONCLUSIONS: From the data presented in this review, we conclude that, in order to select patients that benefit most optimally from demethylating strategies, a comprehensive screening of a large panel of methylation markers, associated with both good as well as poor clinical outcome have to be investigated. Since such panels are not available at this moment, global methylation screening approaches are required to profile such methylated genes. Such methylated gene profiles might be very useful to optimize personalized treatment planning not only in cervical cancer but also in other malignancies.
Authors: W A Peters; P Y Liu; R J Barrett; R J Stock; B J Monk; J S Berek; L Souhami; P Grigsby; W Gordon; D S Alberts Journal: J Clin Oncol Date: 2000-04 Impact factor: 44.544
Authors: Linda J Nicholson; Paul R Smith; Louise Hiller; Peter W Szlosarek; Christopher Kimberley; Jalid Sehouli; Dominique Koensgen; Alexander Mustea; Peter Schmid; Tim Crook Journal: Int J Cancer Date: 2009-09-15 Impact factor: 7.396
Authors: Christian Huisman; G Bea A Wisman; Hinke G Kazemier; Marcel A T M van Vugt; Ate G J van der Zee; Ed Schuuring; Marianne G Rots Journal: Mol Oncol Date: 2013-03-05 Impact factor: 6.603
Authors: L J Melchers; M J A M Clausen; M F Mastik; L Slagter-Menkema; J E van der Wal; G B A Wisman; J L N Roodenburg; E Schuuring Journal: Epigenetics Date: 2015 Impact factor: 4.528
Authors: Leonie Bruine de Bruin; Martijn J A M Clausen; Lorian Slagter-Menkema; Gertruida H de Bock; Johannes A Langendijk; Bert van der Vegt; Bernard F A M van der Laan; Ed Schuuring Journal: Laryngoscope Date: 2021-08-24 Impact factor: 2.970
Authors: Tushar Tomar; Nicolette G Alkema; Leroy Schreuder; Gert Jan Meersma; Tim de Meyer; Wim van Criekinge; Harry G Klip; Heidi Fiegl; Els van Nieuwenhuysen; Ignace Vergote; Martin Widschwendter; Ed Schuuring; Ate G J van der Zee; Steven de Jong; G Bea A Wisman Journal: BMC Med Date: 2017-06-23 Impact factor: 8.775
Authors: Olga Pernía; Cristobal Belda-Iniesta; Veronica Pulido; María Cortes-Sempere; Carlos Rodriguez; Olga Vera; Javier Soto; Julia Jiménez; Alvaro Taus; Federico Rojo; Edurne Arriola; Ana Rovira; Joan Albanell; M Teresa Macías; Javier de Castro; Rosario Perona; Inmaculada Ibañez de Caceres Journal: Epigenetics Date: 2014-11 Impact factor: 4.528
Authors: M J A M Clausen; L J Melchers; M F Mastik; L Slagter-Menkema; H J M Groen; B F A M van der Laan; W van Criekinge; T de Meyer; S Denil; B van der Vegt; G B A Wisman; J L N Roodenburg; E Schuuring Journal: Epigenetics Date: 2016-07-05 Impact factor: 4.528